Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Betamethasone Acetate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 7/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | CNR1 | P21554 | 1/20 | 0.71 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.63 |
| ▸ | PGR | P06401 | 3/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.63 |
| ▸ | AR | P10275 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | APEX1 | P27695 | 1/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | IKBKB | O14920 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betamethasone SCHEMBL13724083 | 0.94 | NR3C1 (0.72) | HIF1ACYP3A4NR3C1LMNACYP2C9 | |
| Dexamethasone SCHEMBL1408949 | 0.94 | NR3C1 (0.72) | HIF1ACYP3A4NR3C1LMNACYP2C9 | |
| Dexamethasone SCHEMBL4743981 | 0.89 | HSD17B10 (0.65) | HIF1ACYP3A4NR3C1LMNACYP2C9 | |
| Triamcinolone SCHEMBL3043158 | 0.89 | HSD17B10 (0.71) | HIF1ACYP3A4NR3C1LMNACYP2C9 | |
| Amcinonide SCHEMBL2864339 | 0.86 | HIF1A (0.74) | HIF1ACYP3A4NR3C1LMNACYP2C9 | |
| Betamethasone Acetate SCHEMBL3681474 | 0.86 | HIF1A (0.94) | HIF1ACYP3A4NR3C1LMNACYP2C9 | |
| Dexamethasone SCHEMBL3135309 | 0.85 | NR3C1 (0.68) | HIF1ACYP3A4NR3C1LMNACYP2C9 | |
| Betamethasone SCHEMBL3224067 | 0.85 | NR3C1 (0.68) | HIF1ACYP3A4NR3C1LMNACYP2C9 | |
| Betamethasone Acetate SCHEMBL10412637 | 0.84 | NR3C1 (1.00) | HIF1ACYP3A4NR3C1LMNACYP2C9 | |
| Betamethasone Acetate SCHEMBL3625942 | 0.84 | NR3C1 (1.00) | HIF1ACYP3A4NR3C1LMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007360-A1 | CONTROLLED RELEASE DELIVERY DEVICE COMPRISING AN ORGANOSOL COAT | Odidi, Isa (CA) | 2008-12-31 | — | — | EP | claimed |
| WO-2007112581-A1 | CONTROLLED RELEASE DELIVERY DEVICE COMPRISING AN ORGANOSOL COAT | ODIDI ISA (CA) | 2007-10-11 | — | — | WO | claimed |
| US-10624858-B2 | Controlled release composition using transition coating, and method of preparing same | INTELLIPHARMACEUTICS CORP (CA) | 2020-04-21 | — | — | US | disclosed |
| US-10314787-B2 | Controlled release delivery device comprising an organosol coat | INTELLIPHARMACEUTICS CORPORATION (CA) | 2019-06-11 | — | — | US | disclosed |
| US-20190083399-A9 | DRUG DELIVERY COMPOSITION | INTELLIPHARMACEUTICS CORPORATION (CA) | 2019-03-21 | — | — | US | disclosed |
| US-20190076363-A1 | CONTROLLED RELEASE DELIVERY DEVICE COMPRISING AN ORGANOSOL COAT | INTELLIPHARMACEUTICS CORPORATION (CA) | 2019-03-14 | — | — | US | disclosed |
| US-10159649-B2 | Controlled release delivery device comprising an organosol coat | INTELLIPHARMACEUTICS CORPORATION (CA) | 2018-12-25 | — | — | US | disclosed |
| US-20170112770-A1 | CONTROLLED RELEASE DELIVERY DEVICE COMPRISING AN ORGANOSOL COAT | INTELLIPHARMACEUTICS CORPORATION (CA) | 2017-04-27 | — | — | US | disclosed |
| US-9561188-B2 | Controlled release delivery device comprising an organosol coat | INTELLIPHARMACEUTICS CORPORATION (CA) | 2017-02-07 | — | — | US | disclosed |
| EP-2007360-B1 | CONTROLLED RELEASE DELIVERY DEVICE COMPRISING AN ORGANOSOL COAT | ODIDI ISA (CA) | 2014-11-26 | — | — | EP | disclosed |
| US-20090304787-A1 | DRUG DELIVERY COMPOSITION | ODIDI ISA | 2009-12-10 | — | — | US | disclosed |
| WO-2007112579-A1 | DRUG DELIVERY COMPOSITION | ODIDI ISA (CA) | 2007-10-11 | — | — | WO | disclosed |
| EP-1831389-A1 | METHOD FOR BIOTRANSFORMATION OF THE CLYCLOSPORIN COMPOUND ISA247 | Isotechnika Inc. (CA) | 2007-09-12 | — | — | EP | disclosed |
| US-20070196914-A1 | Methods for preparing oil bodies comprising active ingredients | SEMBIOSYS GENETICS INC. (CA) | 2007-08-23 | — | — | US | disclosed |
| WO-2006066416-A1 | METHOD FOR BIOTRANSFORMATION OF THE CLYCLOSPORIN COMPOUND ISA247 | ISOTECHNIKA INC. (CA) | 2006-06-29 | — | — | WO | disclosed |
| EP-1670434-A1 | METHODS FOR PREPARING OIL BODIES COMPRISING ACTIVE INGREDIENTS | SemBioSys Genetics Inc. (CA) | 2006-06-21 | — | — | EP | disclosed |
| US-20060039976-A1 | Controlled release composition using transition coating, and method of preparing same | INTELLIPHARMACEUTICS CORP (CA) | 2006-02-23 | — | — | US | disclosed |
| US-20060024361-A1 | Disintegrant assisted controlled release technology | INTELLIPHARMACEUTICS CORP (CA) | 2006-02-02 | — | — | US | disclosed |
| WO-2005030169-A1 | METHODS FOR PREPARING OIL BODIES COMPRISING ACTIVE INGREDIENTS | SEMBIOSYS GENETICS INC. (CA) | 2005-04-07 | — | — | WO | disclosed |
| US-6645528-B1 | Rate of dissolution of drugs can be enhanced by making the drug into a porous matrix form | ACUSPHERE, INC. | 2003-11-11 | — | — | US | disclosed |